Cite
Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.
MLA
Yuan Xue, et al. “Anti-VEGF Agents Confer Survival Advantages to Tumor-Bearing Mice by Improving Cancer-Associated Systemic Syndrome.” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 47, Nov. 2008, pp. 18513–18. EBSCOhost, https://doi.org/10.1073/pnas.0807967105.
APA
Yuan Xue, Religa, P., Cao, R., Jon Hansen, A., Franco Lucchini, Jones, B., Wu, V., Zhenping Zhu, Pytowski, B., Yuxiang Liang, Zhong, W., Vezzoni, P., Rozell, B., & Yihai Cao. (2008). Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 105(47), 18513–18518. https://doi.org/10.1073/pnas.0807967105
Chicago
Yuan Xue, Piotr Religa, Renhai Cao, Anker Jon Hansen, Franco Lucchini, Bernt Jones, Van Wu, et al. 2008. “Anti-VEGF Agents Confer Survival Advantages to Tumor-Bearing Mice by Improving Cancer-Associated Systemic Syndrome.” Proceedings of the National Academy of Sciences of the United States of America 105 (47): 18513–18. doi:10.1073/pnas.0807967105.